Fabricio Conceição

Dr. Fabricio Conceição


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Trends in Parasitology
Verified
Journal Article
Closed access
GMGustavo Marçal Schmidt Garcia Moreira
Gustavo Marçal Schmidt Garcia Moreira
PTPaula de Lima Telmo
Paula de Lima Telmo
MMMarcelo Mendonça
Marcelo Mendonça
ÂMÂngela Nunes Moreira
Ângela Nunes Moreira
AMAlan John Alexander McBride
Alan John Alexander McBride
FCFabricio Conceição
Fabricio Conceição

23 November 2012 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
MMMarcelo Mendonça
Marcelo Mendonça
NCNeida L Conrad
Neida L Conrad
FCFabricio Conceição
Fabricio Conceição
ÂMÂngela N Moreira
Ângela N Moreira
WSWladimir Padilha da Silva
Wladimir Padilha da Silva
Arun K BhuniaArun K Bhunia
Arun K Bhunia
Background: Immunomagnetic separation (IMS) and immunoassays are widely used for pathogen detection. However, novel technology platforms with highly selective antibodies are essential to improve detection sensitivity, specificity and performance. In this study, monoclonal antibodies (MAbs) against Internalin A (InlA) and p30 were generated and used on paramagnetic beads of varying diameters for concentration, as well as on fiber-optic sensor for detection. Results: Anti-InlA MAb-2D12 (IgG2a subclass) was specific for Listeria monocytogenes and L. ivanovii, and p30-specific MAb-3F8 (IgM) was specific for the genus Listeria. At all bacterial concentrations (103–108 CFU/mL) tested in the IMS assay; the 1-μm diameter MyOne beads had significantly higher capture efficiency (P < 0.05) than the 2.8-μm diameter M-280 beads with both antibodies. The highest capture efficiency for MyOne-2D12 (49.2% for 105 CFU/mL) was significantly higher (P < 0.05) than that of MyOne-3F8 (16.6 %) and Dynabeads anti-Listeria antibody (9 %). Furthermore, capture efficiency for MyOne-2D12 was highly specific for L. monocytogenes and L. ivanovii. Subsequently, we captured L. monocytogenes by MyOne-2D12 and MyOne-3F8 from hotdogs inoculated with mono- or co-cultures of L. monocytogenes and L. innocua (10–40 CFU/g), enriched for 18 h and detected by fiber-optic sensor and confirmed by plating, light-scattering, and qPCR assays. The detection limit for L. monocytogenes and L. ivanovii by the fiber-optic immunosensor was 3 × 102 CFU/mL using MAb-2D12 as capture and reporter antibody. Selective media plating, light-scattering, and qPCR assays confirmed the IMS and fiber-optic results. Conclusions: IMS coupled with a fiber-optic sensor using anti-InlA MAb is highly specific for L. monocytogenes and L. ivanovii and enabled detection of these pathogens at low levels from buffer or food.

21 November 2016 in Toxins
Verified
Journal Article
Open access
PDF file
MFMarcos Roberto A. Ferreira
Marcos Roberto A. Ferreira
GMGustavo Marçal S. G. Moreira
Gustavo Marçal S. G. Moreira
CCCarlos Eduardo Pouey da Cunha
Carlos Eduardo Pouey da Cunha
MMMarcelo Mendonça
Marcelo Mendonça
Felipe Masiero SalvaraniFelipe Masiero Salvarani
Felipe Masiero Salvarani
FCFabricio Conceição
Fabricio Conceição
Clostridium perfringens is a spore-forming, commensal, ubiquitous bacterium that is present in the gastrointestinal tract of healthy humans and animals. This bacterium produces up to 18 toxins. The species is classified into five toxinotypes (A–E) according to the toxins that the bacterium produces: alpha, beta, epsilon, or iota. Each of these toxinotypes is associated with myriad different, frequently fatal, illnesses that affect a range of farm animals and humans. Alpha, beta, and epsilon toxins are the main causes of disease. Vaccinations that generate neutralizing antibodies are the most common prophylactic measures that are currently in use. These vaccines consist of toxoids that are obtained from C. perfringens cultures. Recombinant vaccines offer several advantages over conventional toxoids, especially in terms of the production process. As such, they are steadily gaining ground as a promising vaccination solution. This review discusses the main strategies that are currently used to produce recombinant vaccines containing alpha, beta, and epsilon toxins of C. perfringens, as well as the potential application of these molecules as vaccines for mammalian livestock animals.

19 June 2015 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
RFRodrigo Correa França
Rodrigo Correa França
FCFabricio Conceição
Fabricio Conceição
MMMarcelo Mendonça
Marcelo Mendonça
LHLouise Haubert
Louise Haubert
GSGabriela Sabadin
Gabriela Sabadin
ÂMÂngela Nunes Moreira
Ângela Nunes Moreira

23 March 2016 in Scientific Reports
Verified
Journal Article
Open access
GMGustavo Marçal Schmidt Garcia Moreira
Gustavo Marçal Schmidt Garcia Moreira
Felipe Masiero SalvaraniFelipe Masiero Salvarani
Felipe Masiero Salvarani
CCCarlos Eduardo Pouey da Cunha
Carlos Eduardo Pouey da Cunha
MMMarcelo Mendonça
Marcelo Mendonça
ÂMÂngela Nunes Moreira
Ângela Nunes Moreira
FCFabricio Conceição
Fabricio Conceição
Clostridium perfringens is an anaerobic bacterium that produces several toxins. Of these, the alpha, beta, and epsilon toxins are responsible for causing the most severe C. perfringens-related diseases in farm animals. The best way to control these diseases is through vaccination. However, commercially available vaccines are based on inactivated toxins and have many production drawbacks, which can be overcome through the use of recombinant antigens. In this study, we produced recombinant alpha, beta, and epsilon toxins in Escherichia coli to formulate a trivalent vaccine. Its effectiveness was evaluated through a potency test in rabbits, in which the vaccine generated 9.6, 24.4, and 25.0 IU/mL of neutralizing antibodies against the respective toxins. Following this, cattle, sheep, and goats received the same formulation, generating, respectively, 5.19 ± 0.48, 4.34 ± 0.43, and 4.70 ± 0.58 IU/mL against alpha toxin, 13.71 ± 1.17 IU/mL (for all three species) against beta toxin, and 12.74 ± 1.70, 7.66 ± 1.69, and 8.91 ± 2.14 IU/mL against epsilon toxin. These levels were above the minimum recommended by international protocols. As such, our vaccine was effective in generating protective antibodies and, thus, may represent an interesting alternative for the prevention of C. perfringens-related intoxications in farm animals.

31 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LGLuciana A. F. Gil
Luciana A. F. Gil
CCCarlos Eduardo P. da Cunha
Carlos Eduardo P. da Cunha
GMGustavo M. S. G. Moreira
Gustavo M. S. G. Moreira
FSFelipe M. Salvarani
Felipe M. Salvarani
RARonnie A. Assis
Ronnie A. Assis
FCFabricio Conceição
Fabricio Conceição
Bovine botulism is a fatal disease that is caused by botulinum neurotoxins (BoNTs) produced by Clostridium botulinum serotypes C and D and that causes great economic losses, with nearly 100% lethality during outbreaks. It has also been considered a potential source of human food-borne illness in many countries. Vaccination has been reported to be the most effective way to control bovine botulism. However, the commercially available toxoid-based vaccines are difficult and hazardous to produce. Neutralizing antibodies targeted against the C-terminal fragment of the BoNT heavy chain (HC) are known to confer efficient protection against lethal doses of BoNTs. In this study, a novel recombinant chimera, consisting of Escherichia coli heat-labile enterotoxin B subunit (LTB), a strong adjuvant of the humoral immune response, fused to the HC of BoNT serotypes C and D, was produced in E. coli. Mice vaccinated with the chimera containing LTB and an equivalent molar ratio of the chimera without LTB plus aluminum hydroxide (Al(OH)3) developed 2 IU/mL of antitoxins for both serotypes. Guinea pigs immunized with the recombinant chimera with LTB plus Al(OH)3 developed a protective immune response against both BoNT/C (5 IU/mL) and BoNT/D (10 IU/mL), as determined by a mouse neutralization bioassay with pooled sera. The results achieved with guinea pig sera fulfilled the requirements of commercial vaccines for prevention of botulism, as determined by the Brazilian Ministry of Agriculture, Livestock and Food, Supply. The presence of LTB was essential for the development of a strong humoral immune response, as it acted in synergism with Al(OH)3. Thus, the vaccine described in this study is a strong candidate for the control of botulism in cattle.